Home
Scholarly Works
A randomized phase II trial of pyrotinib plus...
Conference

A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab

Authors

Xu B; Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J

Volume

78

Publisher

AMER ASSOC CANCER RESEARCH

Publication Date

February 1, 2018

Name of conference

San Antonio Breast Cancer Symposium

Conference place

TX, San Antonio

Conference start date

December 5, 2017

Conference end date

December 9, 2017

Conference proceedings

CANCER RESEARCH

Issue

4

ISSN

0008-5472

Contact the Experts team